Biosimilar rhG-CSFs: how similar are they?

  title={Biosimilar rhG-CSFs: how similar are they?},
  author={Patricia Gravel and Aarti C. Naik and J. -Y. Le Cotonnec},
  journal={Targeted Oncology},
Biosimilars are more affordable copycat versions of originator biological products in much the same way as generics are copies of small molecule pharmaceuticals. However, while generics are approved on the basis of structural and pharmacokinetic equivalence, the intricate structure of biological medicinal products and the complex nature of their manufacturing process in living organisms impose a separate, and more stringent, regulatory approval process. The aims of this article are (a) to… CONTINUE READING